Analyst Price Target is $7.50
▲ +305.41% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Trevi Therapeutics in the last 3 months. The average price target is $7.50, with a high forecast of $9.00 and a low forecast of $6.00. The average price target represents a 305.41% upside from the last price of $1.85.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Trevi Therapeutics. This Buy consensus rating has held steady for over two years.